DEA Proposes Changes to Drug Quota Applications
Published Date: 5/20/2026
Proposed Rule
Summary
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
Analyzed Economic Effects
5 provisions identified: 1 benefits, 3 costs, 1 mixed.
New Quota Application Timeline Reporting
If you are a bulk or non-bulk manufacturer applying for DEA quotas, you must provide new production-timeline details on quota applications (DEA Form 189 for bulk manufacturers; DEA Form 250 for non-bulk manufacturers). DEA lists the required items: desired individual manufacturing quota (bulk only), time to start production after receiving DEA's quota letter, time to receive API after quota letter (procurement), time to perform the production cycle, time to ship finished goods to the next registrant, supplier of the basic class/chemical (if from another registrant), and any additional relevant factors.
Better Data to Prevent Drug Shortages
DEA says the new application information and subcategory changes will give the agency better visibility into manufacturing cycles and domestic vs. export use, enabling DEA to adjust quotas more quickly to anticipate and help prevent drug shortages that affect medical and scientific needs.
Domestic vs. Export Quota Split
DEA will split certain quota subcategories so manufacturers must state whether quota is for domestic use or for lawful export. The rule bifurcates 'Quota for Commercial Sale', 'Quota for Product Development', and 'Quota for Packaging/Repackaging and Labeling/Relabeling' into domestic and export subcategories (e.g., 'Quota for Domestic Commercial Sale' and 'Quota for Commercial Manufacturing for Export').
Estimated Time and Dollar Burden
DEA estimates the new information will add about 20 minutes per DEA Form 189 or 250 to complete, with a loaded median hourly cost of $89.42 for a purchasing manager, producing an estimated per-application cost of $29.81. Using 2022 application counts (875 Form 189 and 2,514 Form 250), DEA estimates an annual total cost of $101,026.
Small-Entity Impact Finding
DEA certifies under the Regulatory Flexibility Act that the proposed rule will not have a significant economic impact on a substantial number of small entities. DEA estimates the rule would affect 38 of 635 small entities in NAICS 325411 and 272 of 1,080 small entities in NAICS 325412, with estimated economic impacts of 0.095% and 0.022% of annual receipts for those industries, respectively.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20226, By Grace Inc. Counseling Services; Decision and Order
By Grace Inc. Counseling Services in Baltimore faced losing its DEA license because it didn’t keep good records and lied about its owner’s past drug conviction. After a hearing, the DEA decided to revoke their registration, meaning they can’t legally handle controlled substances anymore. This affects the clinic’s ability to operate and could impact patients relying on their services.
2026-20227, St. Michael's Pharmacy; Decision and Order
St. Michael's Pharmacy in Texas had its DEA license suspended and is facing revocation because it kept filling risky drug prescriptions without fixing obvious warning signs of abuse. This affects the pharmacy’s ability to legally handle controlled substances and could impact patients relying on it. The pharmacy must now deal with these serious legal actions, which started in late 2025 and could lead to permanent closure or fines.
2026-20084, Extension of Reexportation Period.
The DEA is proposing to give companies more time—up to 365 days instead of 180—to send controlled substances back out of the European Economic Area. This change helps businesses avoid rushing and reduces stress around shipping deadlines. If you handle these substances, you can share your thoughts by November 30, 2026.
Previous / Next Documents
Previous: 2026-10086, Extending the Compliance Deadline for the PFOA and PFOS Maximum Contaminant Levels
The EPA is giving water systems more time to meet safety rules for two harmful chemicals, PFOA and PFOS, by extending the deadline from April 2029 to April 2031 if they ask for it. This helps water providers get ready without rushing, keeping our drinking water safe. The EPA wants your thoughts and will hold a public hearing in July 2026 to hear from everyone.
Next: 2026-10161, Significant New Use Rules on Certain Chemical Substances (26-2); Extension of Comment Period
The EPA is giving folks more time to share their thoughts on new rules about certain chemicals. If you make, import, or use these chemicals in new ways, you have to tell the EPA 90 days before starting. The comment deadline is now July 10, 2026, so don’t miss your chance to speak up!